Name
J11 - From Surviving to Thriving: A Successful Experience of Multisite Medication Assisted Treatment in Integrated Primary Care and Behavioral Health
Date & Time
Saturday, October 26, 2024, 11:15 AM - 11:45 AM
Location Name
Presidio C
Description

Piedmont Health Services (PHS) implemented Medication Assisted Treatment (MAT) for Opioid Use Disorder (OUD) in 2016 at one community health center. Through team-based learning, use of evidence-based practices, and innovating a flexible workflow, we have expanded integrated treatment to eight community health centers (and soon to be nine!). PHS’s successful multisite integration of MAT across clinics shows how MAT care can help patient’s flourish and promote healing across multiple domains.

Speakers
Jill Baron LCSW, LCAS, Lead Behavioral Health Consultant for Substance Use Disorders, Piedmont Health Services, Chapel Hill, NC
Mary Tayloe MSW, LCSW, LCAS, Behavioral Health Consultant, Piedmont Health Services, Chapel Hill, NC
Jill Baron
Content Level
Intermediate
Tags
Collaborative Care Model of Integrated Care, Medical, Opioid management, Patient-centered care or Patient perspectives, Substance abuse management (e.g., alcohol, tobacco, illicit drugs)
Session Type
Concurrent
SIG or Committee
CoCM, PCBH, Medical
Slideshow link
View Slideshow
Handout 1 Link
View Handout 1
Handout 2 Link
View Handout 2
Objective 1
Examine the relationships between patient’s engaged in MAT in primary care and the positive impacts on their mental and physical health.
Objective 2
Review the importance and benefit of behavioral health involvement in MAT to address psychosocial stressors and aid patients in developing healthy coping strategies.
Objective 3
Discuss best practices and recommendations for integrating MAT in primary care to reduce stigma and empower patients to take a central role in their treatment.
Content Reference 1

Du CX, Shi J, Tetrault JM, Madden LM, Barry DT. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine. Family Practice, 24;39(2):234-240 (2022).

Content Reference 2

Rosenberg, H., Grant, J., & Davis, A. K. Acceptance of non-abstinence as an outcome goal for individuals diagnosed with substance use disorders: A narrative review of published research. Journal of Studies on Alcohol and Drugs, 81(4), 405–415 (2020).

Content Reference 3

Wakeman, S.E., McGovern, S., Kehoe, L., Kane, M.T., Powell, E.A., Casey, S.K., Yacorps, G.M., Irvin, J.R., Rodriguez, W., Regan, S. Predictors of engagement and retention in care at a lowthreshold substance use disorder bridge clinic. Journal of Substance Abuse Treatment, 141:108848 (2022).

Content Reference 4

Carter, J., Zevin, B. & Lum, P.J. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. Addict Sci Clin Pract 14, 20 (2019).